Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research
- PMID: 16207892
- PMCID: PMC2632176
- DOI: 10.1093/schbul/sbj007
Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research
Abstract
Over the last decade schizophrenia researchers have turned their attention to earlier identification in the prodromal period of illness. A greater understanding of both risk and protective factors can lead to improved prevention and treatment strategies in this vulnerable population. This research, however, has far-reaching ethical implications. One year follow-up data from 50 individuals who met established criteria for a prodromal state is used to illustrate ethical issues that directly affect clinicians and future research strategies. At 1-year follow-up, the psychotic transition rate was 13%, but it increased in subsequent years with smaller sample sizes. One-half developed an affective psychosis. The converted sample was older (p > 0.05) than the nonconverted sample and more likely to have a premorbid history of substance abuse, as well as higher clinical ratings on "subsyndromal" psychotic items (delusional thinking, suspiciousness, and thought disorder). Despite a lack of conversion, the nonconverted sample remained symptomatic and had a high rate of affective and anxiety disorders with evidence of functional disability. This conversion rate is relatively low compared to similar studies at 1 year. Specific risk factors were identified, but these findings need to be replicated in a larger cohort. By examining the rate of conversion and nonconversion in this sample as an example, we hope to contribute to the discussion of implications for clinical practice and the direction of future research in the schizophrenia prodrome. Finally, our data strengthen the evidence base available to inform the discussion of ethical issues relevant to this important research area.
Figures
Similar articles
-
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophr Res. 2003 May 1;61(1):19-30. doi: 10.1016/s0920-9964(02)00440-1. Schizophr Res. 2003. PMID: 12648732 Clinical Trial.
-
Ethical implications for clinical practice and future research in "at risk" individuals.Curr Pharm Des. 2012;18(4):606-12. doi: 10.2174/138161212799316262. Curr Pharm Des. 2012. PMID: 22239594 Free PMC article. Review.
-
Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort.Early Interv Psychiatry. 2010 Aug;4(3):220-6. doi: 10.1111/j.1751-7893.2010.00183.x. Early Interv Psychiatry. 2010. PMID: 20712727 Free PMC article.
-
Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group.Schizophr Res. 2003 Mar 1;60(1):21-32. doi: 10.1016/s0920-9964(02)00167-6. Schizophr Res. 2003. PMID: 12505135
-
[Are schizophrenic patients being told their diagnosis today in France?].Encephale. 2017 Apr;43(2):160-169. doi: 10.1016/j.encep.2016.01.011. Epub 2016 Jun 29. Encephale. 2017. PMID: 27372353 Review. French.
Cited by
-
Obstetrical complications in people at risk for developing schizophrenia.Schizophr Res. 2008 Jan;98(1-3):307-11. doi: 10.1016/j.schres.2007.05.011. Epub 2007 Oct 25. Schizophr Res. 2008. PMID: 17961986 Free PMC article.
-
Cannabis abuse and risk for psychosis in a prodromal sample.Psychiatry Res. 2007 May 30;151(1-2):151-4. doi: 10.1016/j.psychres.2006.10.001. Epub 2007 Mar 26. Psychiatry Res. 2007. PMID: 17383738 Free PMC article.
-
Disruptions in neural connectivity associated with reduced susceptibility to a depth inversion illusion in youth at ultra high risk for psychosis.Neuroimage Clin. 2016 Oct 2;12:681-690. doi: 10.1016/j.nicl.2016.09.022. eCollection 2016. Neuroimage Clin. 2016. PMID: 27761399 Free PMC article.
-
Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia.Neuropsychiatr Dis Treat. 2013;9:861-8. doi: 10.2147/NDT.S45697. Epub 2013 Jun 19. Neuropsychiatr Dis Treat. 2013. PMID: 23818786 Free PMC article.
-
Childhood onset diagnoses in a case series of teens at clinical high risk for psychosis.J Child Adolesc Psychopharmacol. 2009 Dec;19(6):771-6. doi: 10.1089/cap.2008.0105. J Child Adolesc Psychopharmacol. 2009. PMID: 20035596 Free PMC article.
References
-
- Addington J, Van Mastrigt S, Addington D. Duration of untreated psychosis: impact on 2-year outcome. Psychol Med. 2004;34(2):277–284. - PubMed
-
- Lieberman JA. Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective. Biol Psychiatry. 1999;46(6):729–739. - PubMed
-
- Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry. 1996;30(5):587–599. - PubMed
-
- Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr Res. 2003;60(1):21–32. - PubMed
-
- Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58(2):158–164. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous